Document is current
Any future updates will be listed below
-
Authors
Duncan, Greg J. https://orcid.org/0000-0003-0203-9972
Ingram, Sam D.
Emberley, Katie https://orcid.org/0000-0003-2333-2289
Hill, Jo
Cordano, Christian https://orcid.org/0000-0002-1413-0442
Abdelhak, Ahmed
McCane, Michael
Jenks, Jennifer E. https://orcid.org/0000-0002-3150-3618
Jabassini, Nora
Ananth, Kirtana
Ferrara, Skylar J.
Stedelin, Brittany
Sivyer, Benjamin https://orcid.org/0000-0002-4537-5768
Aicher, Sue A.
Scanlan, Thomas S.
Watkins, Trent A. https://orcid.org/0000-0001-6723-3712
Mishra, Anusha https://orcid.org/0000-0002-3642-5049
Nelson, Jonathan W.
Green, Ari J.
Emery, Ben https://orcid.org/0000-0002-9132-3045
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (R01NS120981, NS061800)
National Multiple Sclerosis Society (FG-1808-32238)
American Heart Association (20CDA35320169)
Fondazione Italiana Sclerosi Multipla (2019/BC/002)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (K01DK121737)
- License Information
-
More Information
Article History
Received: 29 August 2024
Accepted: 7 October 2024
First Online: 23 October 2024
Competing interests
: T.S.S. and B.E. are co-founders of Autobahn Therapeutics, B.E. has received consulting fees from Autobahn Therapeutics and T.S.S. is a Senior Advisor to Autobahn Therapeutics. B.E. and G.J.D. have received licensing fees for the use of <i>Myrf</i> inducible conditional knockout mice. These potential conflicts of interest have been reviewed and managed by OHSU. The remaining authors declare no competing interests.
